QIAGEN N.V. (NYSE:QGEN) – A Quality Stock with Strong Fundamentals

QIAGEN N.V. (NYSE:QGEN) stands out as a potential candidate for quality investors, meeting key criteria for long-term growth, profitability, and financial health. The company, which specializes in molecular diagnostics and life sciences tools, demonstrates strong fundamentals that align with the principles of quality investing.

Key Strengths of QIAGEN

• Revenue and EBIT Growth: Over the past five years, QGEN has delivered solid revenue growth at an annualized rate of 8.27%, while EBIT growth has been even stronger at 9.63%. This indicates improving operational efficiency and profitability.
• High Return on Invested Capital (ROIC): With an ROIC of 29.06%, QGEN efficiently generates returns from its capital investments, placing it well above many industry peers.
• Strong Profit Quality: The company converts net income into free cash flow at an impressive rate, with a five-year average profit quality of 189.74%. This suggests reliable earnings and financial stability.
• Manageable Debt Levels: QGEN’s debt-to-free cash flow ratio stands at 2.77, meaning it could repay its debt in under three years using current cash flows—a sign of financial discipline.

Fundamental Analysis Summary

QIAGEN’s fundamental report highlights a well-balanced profile:

• Profitability: The company scores highly on operating margins (25.02%) and gross margins (63.82%), outperforming most competitors.
• Financial Health: A strong Altman-Z score (4.30) and healthy liquidity ratios indicate low bankruptcy risk.
• Valuation: While not cheap, QGEN trades at reasonable multiples relative to industry averages, with a forward P/E of 17.45.

For investors seeking stable, high-quality businesses, QGEN presents a compelling case.

Our Caviar Cruise screener lists more quality stocks and is updated regularly.

Disclaimer

This is not investing advice. Always conduct your own research before making investment decisions.